Momentum Stock: Mannkind Corporation (MNKD)

Mannkind Corporation

The Biotech Stock Up Over 88%

The overall volume in the last trading session was 13,217,450 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter. It has a market cap of $375.84 Million. The 9 months bullish chart indicates low risk for the $675.20 million company. The stock's short float is around of 31.07% and short ratio is 4.82.

Mannkind Corporation (NASDAQ:MNKD) shares traded on 1.41% above secure line and closed at $5.03. For the current quarter Mannkind Corporation (NASDAQ:MNKD) has high EPS estimates of $-0.13 in contradiction of low EPS estimates of $-0.28. The relative volume of the stock is 2.71. Thanks to an increase of nearly 13.93% in the past one month, the stock price is now outperforming with 26.86% so far on the year - still in strong zone. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. Its weekly performance showed upward trend of 131.8 percent. Currently, MannKind Corporation net profit margin for the 12 months is at 0%. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. The company maintains price to book ratio of 0.00 vs.an industry average at 0.57.

MannKind Corp. (MNKD) shows its Return on Assets (ROA) value of 140.1 percent, while the Return on Equity (ROE) value is -61.2 percent and Return on Investment (ROI) value stands at -396.8 percent.

The Relative Strength Index (RSI) is a very common technical indicator used to determine strengthening and weakening momentum in price action. The stock is now moving above its 20-Day Simple Moving Average of 114.32% with a 50-Day Simple Moving Average of 177.13 percent. A total number of 2 analysts provided estimations over revenues.

EPS Estimate for the next Quarter is -0.21.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -3.5% and a 42.1% success rate.

EPS growth for the next 5 years is 26.8 percent. It depends on 5 financial ratios, which can be calculated from data found on a firm's annual 10K report. It is derived from the P/E - Price Earnings Ratio, in which the profit is replaced by cash flow. In today's article we will discuss both types of volatility and how each type is used. Taking a glance at the relative strength indictor, we note that the 14-day RSI is now at 91.30, the 7-day stands at 95.83, and the 3-day is sitting at 99.30. The company has Beta Value of 3.13 and ATR value of 0.48.

The company last reported its quarterly results on Nov 06 AMC.

MannKind is finally starting to get some respect from Wall Street analysts after the U.S. Food and Drug Administration revised the label of the company's inhaled insulin product, Afrezza, and management successfully executed a common stock for warrant exchange that provided MannKind with some much-needed wiggle room on the financial front.

The company now has an insider ownership of 0.2 Percent and Institutional ownership of 16.1 Percent. Institutional investors and hedge funds own 15.67% of the company's stock.

Latest News